Huntington National Bank Has $651,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

Huntington National Bank lessened its holdings in AstraZeneca PLC (NASDAQ:AZNFree Report) by 7.6% in the third quarter, HoldingsChannel reports. The fund owned 9,612 shares of the company’s stock after selling 785 shares during the period. Huntington National Bank’s holdings in AstraZeneca were worth $651,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Fairfield Bush & CO. bought a new stake in AstraZeneca during the first quarter worth about $28,000. Panagora Asset Management Inc. lifted its position in AstraZeneca by 55.1% during the first quarter. Panagora Asset Management Inc. now owns 11,956 shares of the company’s stock worth $793,000 after purchasing an additional 4,249 shares during the period. BlackRock Inc. lifted its position in AstraZeneca by 22.0% during the first quarter. BlackRock Inc. now owns 7,466,492 shares of the company’s stock worth $495,328,000 after purchasing an additional 1,343,939 shares during the period. Great West Life Assurance Co. Can lifted its position in AstraZeneca by 102.7% during the first quarter. Great West Life Assurance Co. Can now owns 525 shares of the company’s stock worth $36,000 after purchasing an additional 266 shares during the period. Finally, Moors & Cabot Inc. raised its stake in AstraZeneca by 2.8% during the first quarter. Moors & Cabot Inc. now owns 10,841 shares of the company’s stock worth $719,000 after acquiring an additional 292 shares in the last quarter. Institutional investors own 15.68% of the company’s stock.

AstraZeneca Price Performance

AstraZeneca stock opened at $62.26 on Friday. The stock has a market capitalization of $193.03 billion, a price-to-earnings ratio of 32.43, a PEG ratio of 1.15 and a beta of 0.52. AstraZeneca PLC has a 52-week low of $61.70 and a 52-week high of $76.56. The stock’s 50 day moving average price is $66.50 and its two-hundred day moving average price is $66.73. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.60 and a current ratio of 0.79.

AstraZeneca (NASDAQ:AZNGet Free Report) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). The business had revenue of $12.02 billion for the quarter, compared to the consensus estimate of $12.07 billion. AstraZeneca had a return on equity of 30.67% and a net margin of 13.00%. AstraZeneca’s quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.69 earnings per share. On average, equities analysts predict that AstraZeneca PLC will post 4.09 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on the company. Morgan Stanley initiated coverage on AstraZeneca in a research note on Tuesday, January 23rd. They set an “overweight” rating for the company. Jefferies Financial Group downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. HSBC began coverage on AstraZeneca in a research note on Monday, December 18th. They issued a “buy” rating for the company. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $80.00.

Check Out Our Latest Report on AZN

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

See Also

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.